SUPN Supernus Pharmaceuticals, Inc.

XNAS 41.17 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

SUPN $41.17 —
Key stats
$41.17
52-Week Range
$37.54 – $59.68
YTD
-16.78%
IV Rank (30D)
80.85
Straddle Price
$5.35
P/C Vol Ratio
1.67
Market Cap
$2.4B
Open
$41.52
Day Range
$40.73 – $41.85
Volume
368,672
Prev Close
$41.21
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.76
Cost of Equity (CAPM)8.95% (VRP-adj)
WACC8.94%
Volatility Risk Premium+19.8pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+14.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)-10.7%
Book / Price43.8% — banking bias active (P/B is primary)
Gross Margin (TTM)88.1%
FCF Margin (TTM)2.3%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$43.45 (Market Anchor value)
SMA 20 / Bollinger Mid$42.02
Bollinger Width / SMA2035.7% (drives anchor stability)
Net Debt$-0.2B
Market Cap$2B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
78%
20-Day Fair Value
≈ by Nov 20, 2026
$41.41
α +0.4% rank 37%
conviction
30%
40-Day Fair Value
≈ by Dec 21, 2026
$42.36
α +2.7% rank 56%
conviction
80%
60-Day Fair Value
≈ by Jan 19, 2027
$42.32
α +2.6% rank 48%
conviction
78%
MethodImplied PriceWeightDetail
DCF $13.42 13%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.6× · 3 peers
Peer EV/EBITDA $13.57 8% median 19.0× · 3 peers
Peer P/B $62.58 10% median 3.5× · 3 peers
Peer P/S $60.87 10% median 3.8× · 3 peers
Market Anchor (SMA50) $43.45 35% stability 68% (BB-width)
Options Expected (B-L 30d) $42.77 23% 18 strikes · skew +0.39
As of 2026-10-22 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$2.4B
Employees
778
List Date
2012-05-01
CIK
0001356576
Next Earnings
2026-10-29 (After-Close)
Headquarters
Rockville, MD
Homepage
https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan16.91%2.56%9.45%-0.18%5.33%-2.65%5.24%
Feb-10.46%0.63%-9.60%6.60%-14.19%12.20%-2.47%
Mar0.73%8.82%-7.69%10.00%3.18%-6.17%1.48%
Apr13.96%-13.30%1.18%-10.20%2.53%-6.69%-2.09%
May-3.77%-3.50%-10.31%-9.84%-2.31%-3.49%-5.54%
Jun4.16%3.36%-8.80%-3.11%-1.22%3.91%-0.28%
Jul-16.12%8.18%2.64%12.32%10.31%-4.43%2.15%
Aug2.95%8.67%0.47%18.90%27.08%-3.89%9.03%
Sep-4.06%-3.40%-15.14%-10.17%7.30%-1.60%-4.51%
Oct9.66%2.30%-12.06%6.47%14.76%-2.25%*3.15%
Nov-1.22%7.02%13.97%7.65%-18.15%--1.85%
Dec-5.48%-3.65%4.93%-3.08%11.19%--0.78%
Total2.17%16.34%-30.43%22.36%44.95%-15.27%6.69%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $41.91
SMA 50: $43.31
SMA 200: $47.58
Current: $41.15
EMA 12: $41.10
EMA 26: $41.90
MACD: -0.7975 | Signal: -0.0220
BEARISH
ADX (14): 26.05
TREND
+DI: 15.05
−DI: 24.26

Momentum Oscillators

RSI (14): 45.94
NEUTRAL
Stoch %K: 61.39
Stoch %D: 48.97
Williams %R: -38.45

Volume & Volatility

BB Upper: $45.02
BB Lower: $38.79
NEUTRAL
OBV: 7,999,693
Vol SMA 20: 863,296
Vol ROC: -47.20%
ATR: $1.64
True Range: $1.12
HV 20: 40.0%
HV 30: 36.1%
HV 60: 37.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

SUPN Stock Analysis Report

Supernus Pharmaceuticals Inc.

Executive Summary

Overall Assessment: NEUTRAL (Confidence: 6/10)

SUPN presents a conflicted technical setup with mixed fundamental signals. The stock is caught in a range-bound environment with bearish momentum indicators (MACD histogram at -0.49, -DI at 20.45 exceeding +DI at 15.54) offset by extremely low systematic risk (beta 0.44) and defensive characteristics. Recent news sentiment is bifurcated—positive M&A activity (Sage Therapeutics tender offer completion on 2025-07-28 and conference participation) contrasts sharply with a shareholder litigation investigation initiated on the same day as a significant price move (2026-08-03).

Primary Drivers: M&A integration narrative vs. shareholder dispute concerns; defensive positioning in volatile market; range-bound technical consolidation

Primary Risks: Litigation overhang; break below $40.88 support; MACD bearish divergence; deteriorating volume momentum (-15.68% volume rate of change)

Technical Analysis

Trend Direction

Short-term (1-4 weeks): BEARISH/NEUTRAL

  • Price at $43.05 sits below the 20-day SMA ($42.65) — initial bearish signal, though only marginally
  • However, price is above the lower Bollinger Band ($40.88), indicating room before oversold conditions
  • ADX at 15.15 signals a range-bound regime (not a trending market), reducing reliability of directional signals

Medium-term (1-3 months): BEARISH

  • Price at $43.05 is meaningfully below the 50-day SMA ($44.48) by -1.43 points (-3.2%)
  • The 50/200 SMA spread shows the 50-day is above the 200-day ($44.48 vs $48.11), indicating prior uptrend has stalled but not reversed into downtrend
  • Bearish crossover structure forming

Long-term (3-12 months): BEARISH

  • Price at $43.05 remains significantly below the 200-day SMA at $48.11 (5.06 point or -10.5% gap)
  • This suggests the stock has not recovered to longer-term equilibrium
  • 2025-12-16 news indicates stock is "20% below 2018 highs," reflecting structural underperformance

Support & Resistance Levels

| Level | Type | Analysis | |-------|------|----------| | $40.88 | Support (Lower BB) | Critical near-term support; break below triggers potential acceleration lower to $39-40 range | | $42.65 | Support/Pivot (20 SMA) | Active support zone; price currently hovering at this level | | $44.42 | Resistance (Upper BB) | Upper Bollinger Band resistance; price needs conviction to break above | | $44.48 | Resistance (50 SMA) | Medium-term moving average resistance; reclaiming this signals trend improvement | | $48.11 | Major Resistance (200 SMA) | Strong long-term resistance; represents psychological mean reversion target |

Momentum Signals

RSI (14): 48.09 — NEUTRAL

  • Reading is precisely mid-range (neutral zone: 30-70)
  • Not overbought (>70) or oversold (<30)
  • Indicates balanced buying/selling pressure with no extreme condition
  • No immediate mean reversion signal implied

MACD: -0.37 (MACD line) vs 0.13 (Signal line) — BEARISH DIVERGENCE

  • MACD line is below the signal line by -0.50 points (histogram of -0.49)
  • This represents a bearish crossover signal or sustained bearish position
  • Negative histogram indicates downside momentum is present, though not extreme in magnitude
  • Confluence with price below 20-day SMA strengthens bearish implication

Bollinger Bands: NEUTRAL (Width 8.30, Mid at $42.65)

  • Width of 8.30 is moderate—not in squeeze mode (would indicate compression/breakout pending) nor in extreme expansion
  • Price at $43.05 sits in upper-middle portion of bands, between the midline and upper band
  • Position suggests neither overbought nor oversold; no squeeze or extreme volatility regime
  • Signal: Range-bound consolidation

Volume Analysis

Critical Volume Weakness:

  • Volume Rate of Change: -15.68% — Significant deterioration
  • 20-day Volume SMA: 699,237 shares
  • This negative rate of change signals declining institutional interest and weakening conviction behind price action
  • Declining volume during consolidation is bearish signal (suggests buyers are exhausted)

On-Balance Volume: 10,512,083.50

  • Cumulative volume indicator is positive in absolute terms but trajectory is concerning given -15.68% rate of change
  • Combined with MACD bearish crossover and volume decline, suggests potential for further downside as institutions reduce exposure

Assessment: Volume deterioration contradicts any near-term bullish case and reinforces bearish technical setup. Low volume makes breakouts less reliable.

News & Sentiment Analysis

Recent Headlines Summary

| Date | Headline | Sentiment | Significance | |------|----------|-----------|--------------| | 2026-08-03 | Why SUPN Topped Market | POSITIVE | Unexplained rally; likely tied to M&A or broader catalyst | | 2026-08-03 | Halper Sadeh Investigating Fair Deals | NEGATIVE | Same-day litigation announcement; major overhang | | 2025-07-28 | HSR Waiting Period Expires (Sage Deal) | POSITIVE | M&A milestone reached; deal closer to close | | 2025-12-16 | SUPN Up 31% YoY but 20% Below 2018 | NEUTRAL | Structural underperformance narrative | | 2026-05-06 | BofA Conference Participation | POSITIVE | Investor engagement; minor catalyst | | 2026-02-23 | March Conference Participation | NEUTRAL | Routine IR activity |

Sentiment Assessment

Aggregate Sentiment: MIXED NEGATIVE

  • Positive signals (3): Sage M&A progression, conference participation, market outperformance on 8/3
  • Negative signals (1): Shareholder litigation investigation
  • Neutral signals (2): Routine conference participation, YoY performance narrative

Critical Timing Observation: The 2026-08-03 dual announcement is significant:

  • Market-topping performance occurred on the same day as litigation investigation announcement
  • This suggests the positive catalyst (likely M&A completion news or positive clinical/regulatory update) overwhelmed the litigation concern on that specific day
  • However, litigation announcement represents a persistent overhang that could resurface as headline risk if market sentiment shifts

Catalyst Identification

IMMEDIATE (1-7 days):

  • Litigation resolution (Halper Sadeh investigation outcome timeline unknown)
  • Any Sage Therapeutics deal closing announcement
  • Management commentary clarifying shareholder concerns

NEAR-TERM (1-4 weeks):

  • Possible earnings announcement or guidance update
  • Resolution/settlement of shareholder litigation
  • Integration updates on Sage acquisition

MEDIUM-TERM (1-3 months):

  • Sage Therapeutics full integration milestones
  • Product launch or pipeline update announcements
  • Clinical trial result releases (if applicable)

Market Narrative Analysis

Narrative Conflict: The technical signals (bearish MACD, volume deterioration, price below 20/50-day MAs) conflict directly with positive M&A news (Sage deal progression). This suggests:

  1. M&A enthusiasm has already been priced in — the 31% YoY gain likely reflects this
  2. Current pullback represents profit-taking or consolidation after the rally
  3. Litigation uncertainty is creating hesitation — investors may be waiting for clarity before re-engaging
  4. Technical weakness during positive news is bearish — typically strong news should attract buying; instead, volume is declining

This setup suggests the market is pricing in deal closure but facing execution uncertainty on the litigation front.

Risk & Volatility Assessment

Beta Interpretation: 0.44 (Defensive)

Key Findings:

  • Beta of 0.44 means SUPN moves only **44%
Generated
News
All SUPN news →
Earnings History
19 of 21 under expected move
Avg Expected Move
11.02%
Avg Actual Move
4.06%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-24 After-Close 7.43% 4.82% 0.65x Within
2021-04-28 After-Close 9.94% 0.29% 0.03x Within
2021-10-28 After-Close 12.70% 1.12% 0.09x Within
2022-02-22 After-Close 15.84% 1.74% 0.11x Within
2022-04-13 After-Close 7.17% 4.69% 0.65x Within
2023-02-10 After-Close 10.34% 1.99% 0.19x Within
2023-07-24 After-Close 8.92% 0.77% 0.09x Within
2023-10-25 After-Close 11.10% 2.28% 0.21x Within
2024-02-13 After-Close 4.43% 1.66% 0.37x Within
2024-04-24 After-Close 9.62% 3.14% 0.33x Within
2024-08-06 After-Close 13.45% 14.49% 1.08x Exceeded
2024-10-21 Pre-Market 16.79% 2.52% 0.15x Within
2024-11-04 After-Close 6.20% 0.12% 0.02x Within
2025-02-25 After-Close 13.26% 2.74% 0.21x Within
2025-04-23 After-Close 11.02% 1.65% 0.15x Within
2025-07-22 Pre-Market 10.61% 1.69% 0.16x Within
2025-11-04 After-Close 11.49% 17.35% 1.51x Exceeded
2026-02-24 After-Close 15.81% 5.67% 0.36x Within
2026-05-05 After-Close 11.49% 4.59% 0.40x Within
2026-08-04 After-Close 10.52% 8.46% 0.80x Within
2026-10-19 After-Close 13.30% 3.49% 0.26x Within

Earnings calendar: this week’s reports with expected vs actual moves →

SUPN Options Activity & IV Rank

SUPN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 57.2%
7-DTE IV: —
Expected Move: $5.35
7-DTE Move: $5.35
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 3
Put Volume: 5
P/C Volume: 1.667
BEARISH
Call OI: 2
Put OI: 7
P/C OI: 3.5
Total OI: 9

ATM Options Pricing

ATM Call: $2.75
ATM Put: $2.60
Call %: 6.7%
Put %: 6.3%

Chain Summary

Chain Volume: 870
Chain OI: 1,775
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 29th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
29%
vs own history
GEX tilt
-0.03
OI-weighted, today
Vanna tilt
-0.70
δ-sensitivity to IV
Charm tilt
+0.62
δ-decay vs time
Vanna tilt -0.70: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.62: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 11 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
No data
30 DTE / 10d —
— pts EXTREME
ATM 57.8% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)80.8HighOct 22
Straddle Price (30 DTE)$5.35Oct 22
Beta Analysis

Risk Metrics

Beta: 0.5363
Alpha: -21.36%
Correlation: 0.1849
R-Squared: 3.4%
Stock Volatility: 37.0%
Market Volatility: 12.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own SUPN
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$179.2M
0.12%
#168 of 3716+16.2%13F
Renaissance Technologies Hedge fund
Jim Simons
$68.8M
0.09%
#239 of 3138-13.3%13F
Citadel Hedge fund
Ken Griffin
$63.9M
0.04%
#569 of 6285-8.0%13F
Rockefeller Capital Management Family office
Rockefeller family
$71K
0.00%
#3176 of 4729-21.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

SUPN Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 57,180,450 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

347 filers66,285,125 shares$3.10B value115.92% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 9,350,046 $434.87M 14.03% 16.35% 2026-06-30
2 Vanguard Group Inc Custodian 6,048,496 $300.61M 9.70% 10.58% 2025-12-31
3 Millennium Management LLC Custodian 3,853,212 $179.21M 5.78% 6.74% 2026-06-30
4 Vanguard Portfolio Management LLC 3,305,429 $153.74M 4.96% 5.78% 2026-06-30
5 ARMISTICE CAPITAL, LLC 2,646,201 $123.07M 3.97% 4.63% 2026-06-30
6 Vanguard Capital Management LLC 2,516,721 $117.05M 3.78% 4.40% 2026-06-30
7 State Street Corp 2,459,828 $114.41M 3.69% 4.30% 2026-06-30
8 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 2,378,329 $110.62M 3.57% 4.16% 2026-06-30
9 Dimensional Fund Advisors LP Custodian 2,078,090 $96.65M 3.12% 3.63% 2026-06-30
10 Geode Capital Management, LLC Custodian 1,570,088 $73.04M 2.36% 2.75% 2026-06-30
11 Stephens Investment Management Group LLC 1,485,821 $69.11M 2.23% 2.60% 2026-06-30
12 RENAISSANCE TECHNOLOGIES LLC 1,478,180 $68.75M 2.22% 2.59% 2026-06-30
13 LOOMIS SAYLES & CO L P 1,475,192 $68.61M 2.21% 2.58% 2026-06-30
14 Citadel Advisors LLC Custodian 1,373,982 $63.90M 2.06% 2.40% 2026-06-30
15 Two Sigma Investments, LP Custodian 1,184,378 $55.09M 1.78% 2.07% 2026-06-30
16 GW&K Investment Management, LLC 1,037,242 $48.24M 1.56% 1.81% 2026-06-30
17 Sofinnova Investments, Inc. 1,036,328 $48.20M 1.55% 1.81% 2026-06-30
18 Qube Research & Technologies Ltd 922,166 $42.89M 1.38% 1.61% 2026-06-30
19 Morgan Stanley Custodian 876,841 $40.78M 1.32% 1.53% 2026-06-30
20 Goldman Sachs Group Inc Custodian 819,432 $38.11M 1.23% 1.43% 2026-06-30
21 D. E. Shaw & Co., Inc. Custodian 767,668 $35.70M 1.15% 1.34% 2026-06-30
22 Northern Trust Corp Custodian 733,374 $34.11M 1.10% 1.28% 2026-06-30
23 Woodline Partners LP 708,276 $32.94M 1.06% 1.24% 2026-06-30
24 Charles Schwab Investment Management, Inc. 703,552 $32.72M 1.06% 1.23% 2026-06-30
25 Bank of America Corp Custodian 621,102 $28.89M 0.93% 1.09% 2026-06-30
3 filers$980.01K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $939.50K 95.87% 2026-06-30
2 Raiffeisen Bank International AG $31.21K 3.18% 2026-06-30
3 Simplex Trading, LLC Custodian $9.30K 0.95% 2026-06-30
5 filers$6.64M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $3.45M 51.89% 2026-06-30
2 Citadel Advisors LLC Custodian $2.12M 31.86% 2026-06-30
3 Jane Street Group, LLC Custodian $674.39K 10.15% 2026-06-30
4 Simplex Trading, LLC Custodian $348.82K 5.25% 2026-06-30
5 GROUP ONE TRADING LLC Custodian $55.81K 0.84% 2026-06-30

SUPN Insider Trading (Form 4)

Latest: 2026-08-14
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-14 Jonathan Rubin SVP, Chief Medical Officer Mixed +387 $46.57 -$16.9K EDGAR
2026-08-14 Frank Mottola SVP, Chief Tech. Ops. Officer Mixed +853 $46.57 -$37.1K EDGAR
2026-08-14 Timothy C Dec Senior Vice-President & CFO Mixed +646 $46.57 -$28.1K EDGAR
2026-08-14 Padmanabh P. Bhatt Sr. VP of IP, CSO Mixed +1,342 $46.57 -$53.9K EDGAR
2026-08-14 Jack A. Khattar President, CEO Mixed +17,207 $46.57 -$588.7K EDGAR
2026-07-31 Jonathan Rubin SVP, Chief Medical Officer Grant (A) +750 RSU — EDGAR
2026-07-31 Jack A. Khattar President, CEO Grant (A) +29,849 RSU — EDGAR
2026-07-31 Timothy C Dec Senior Vice-President & CFO Grant (A) +1,250 RSU — EDGAR
2026-07-31 Padmanabh P. Bhatt Sr. VP of IP, CSO Grant (A) +2,500 RSU — EDGAR
2026-07-31 Frank Mottola SVP, Chief Tech. Ops. Officer Grant (A) +1,650 RSU — EDGAR
2026-03-18 Padmanabh P. Bhatt Sr. VP of IP, CSO Mixed — $43.27 -$1.50M EDGAR
2026-03-16 Frederick M. Hudson Director Sell (S) −5,369 $50.61 -$271.7K EDGAR
2026-03-16 Jack A. Khattar President, CEO Mixed −35,000 $50.37 -$1.76M EDGAR
2026-03-10 Timothy C Dec Senior Vice-President & CFO Mixed +3,117 $54.73 -$157.8K EDGAR
2026-03-10 Frank Mottola SVP, Chief Tech. Ops. Officer Mixed +334 $54.22 -$185.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

SUPN Insider Holdings

10 insiders · @ $41.15
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Charles W Newhall III Director 6,365,369 $261.93M $20.00M 32 2026-02-25
2 Jack A. Khattar President, CEO 2,229,093 $91.73M -$39.04M 95 2026-08-14
3 Frederick M. Hudson Director 60,413 $2.49M -$1.16M 29 2026-03-16
4 Georges Gemayel Director 28,159 $1.16M -$2.35M 22 2026-03-09
5 Carrolee Barlow Director 27,045 $1.11M $0 14 2026-02-25
6 Padmanabh P. Bhatt Sr. VP of IP, CSO 19,795 $814.6K -$20.09M 73 2026-08-14
7 Frank Mottola SVP, Chief Tech. Ops. Officer 19,544 $804.2K -$2.71M 33 2026-08-14
8 Jonathan Rubin SVP, Chief Medical Officer 14,342 $590.2K -$36.3K 24 2026-08-14
9 Timothy C Dec Senior Vice-President & CFO 9,129 $375.7K -$524.1K 27 2026-08-14
10 William Todd Horich SVP, Commercial Operations 4,439 $182.7K -$483.8K 1 2026-03-10
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

SUPN Board & Officers

As of SEC filings through Aug 14, 2026

Directors 6

Officers 6

Changes in the last 10 years (17)
Mar 1, 2026William Todd Horich became SVP, Commercial Operations
Sep 15, 2025Frank Mottola listed as SVP, Chief Tech. Ops. Officer (previously SVP, Quality, GMP, Ops, IT) in SEC filings
Apr 22, 2024The company announced the departure of John M Siebert from the board in an SEC filing
Feb 14, 2024The company announced the departure of Tami Tillotson Martin as Sr. V.P., Regulatory Affairs in an SEC filing
Nov 16, 2023Frank Mottola listed as SVP, Quality, GMP, Ops, IT (previously Sr VP, Quality, GMP Oper. & IT) in SEC filings
Aug 17, 2023Bethany Sensenig became a director
Mar 16, 2023Frank Mottola listed as Sr VP, Quality, GMP Oper. & IT (previously SVP, Quality, GMP, Ops, IT) in SEC filings
Aug 23, 2021Timothy C Dec became Senior Vice-President & CFO
Feb 23, 2021Frank Mottola listed as SVP, Quality, GMP, Ops, IT (previously Sr VP, Quality, GMP Oper. & IT) in SEC filings
Jan 1, 2021Jonathan Rubin became SVP, Chief Medical Officer
Oct 12, 2020James Patrick Kelly became Executive Vice-President & CFO
Feb 25, 2020Tami Tillotson Martin listed as Sr. V.P., Regulatory Affairs (previously VP of Regulatory Affairs) in SEC filings
Feb 25, 2020Stefan K.F. Schwabe listed as Executive Vice President & CMO (previously Executive Vice President R&D) in SEC filings
Feb 21, 2020Frank Mottola became Sr VP, Quality, GMP Oper. & IT
Feb 26, 2019Gregory S Patrick listed as Sr.VP, Chief Financial Officer (previously VP, Chief Financial Officer) in SEC filings
Jun 27, 2018Carrolee Barlow became a director
Apr 9, 2018Victor Vaughn listed as Sr. VP of Sales and Marketing (previously Sr. VP of Sales) in SEC filings
Not reported recently (5)
  • James Patrick Kelly · Last reported as Executive Vice-President & CFO in an SEC filing dated Feb 23, 2021
  • Stefan K.F. Schwabe · Last reported as Executive Vice President & CMO in an SEC filing dated Dec 22, 2020
  • Gregory S Patrick · Last reported as Sr.VP, Chief Financial Officer in an SEC filing dated Nov 10, 2020
  • Victor Vaughn · Last reported as Sr. VP of Sales and Marketing in an SEC filing dated Apr 20, 2018
  • William A. Nuerge · Last reported as a director in an SEC filing dated Jun 15, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

SUPN Proposed Insider Sales (Form 144)

Latest: 2026-03-17
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-03-17 PADMANABH P BHATT Officer 57,250 $2.87M 2026-03-17 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-16 PADMANABH P BHATT Officer 50,000 $2.50M 2026-03-16 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-13 THE KBT TRUST U/A DTD 12/30/2010 Director, Officer 35,000 $1.77M 2026-03-13 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-12 FREDERICK M HUDSON Director 5,369 $271.8K 2026-03-12 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-10 WILLIAM TODD HORICH Officer 4,439 $244.1K 2026-03-10 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-09 WILLIAM TODD HORICH Officer 4,438 $239.7K 2026-03-09 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-09 FRANK MOTTOLA Officer 1,623 $87.1K 2026-03-09 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-06 GEORGES GEMAYEL Director 8,787 $465.8K 2026-03-06 Morgan Stanley Smith Barney LLC … — EDGAR
2026-03-05 GEORGES GEMAYEL Director 10,000 $537.1K 2026-03-05 Morgan Stanley Smith Barney LLC … — EDGAR
2026-02-19 BETHANY SENSENIG Director 4,475 $224.6K 2026-02-19 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
112 ETFs hold SUPN
25 shown · $606.48M total exposure · 0.13% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJR iShares Core S&P Small-Cap ETF iShares (BlackRock) 0.14% $142.7M $103.1B 2026-10-20
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $76.0M — 2026-09-30
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.08% $58.4M $75.1B 2026-10-20
4 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.03% $53.5M — 2026-09-30
5 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.05% $34.8M — 2026-09-30
6 VXF Vanguard Extended Market ETF Vanguard 0.03% $28.3M — 2026-09-30
7 SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF SPDR (State Street) 0.14% $21.8M $15.7B 2026-10-20
8 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.14% $19.7M $13.7B 2026-10-20
9 DFAS Dimensional US Small Cap ETF Dimensional 0.06% $18.9M — 2026-10-20
10 DFAT Dimensional US Targeted Value ETF Dimensional 0.05% $16.4M — 2026-10-20
11 IJT iShares S&P Small-Cap 600 Growth ETF iShares (BlackRock) 0.20% $15.2M $7.6B 2026-10-20
12 VTWO Vanguard Russell 2000 ETF Vanguard 0.08% $14.1M — 2026-09-30
13 SCHA Schwab U.S. Small-Cap ETF Nport 0.06% $12.7M — 2026-05-31
14 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.01% $12.1M — 2026-10-20
15 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.17% $11.0M $6.6B 2026-10-20
16 SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF SPDR (State Street) 0.20% $9.4M $4.6B 2026-10-20
17 XPH State Street® SPDR® S&P® Pharmaceuticals ETF SPDR (State Street) 1.98% $8.9M $452.3M 2026-10-20
18 VIOO Vanguard S&P Small-Cap 600 ETF Vanguard 0.15% $8.9M — 2026-09-30
19 DFMC Dimensional US Micro Cap ETF Dimensional 0.12% $8.7M — 2026-10-20
20 IHE iShares U.S. Pharmaceuticals ETF iShares (BlackRock) 0.52% $8.1M $1.5B 2026-10-20
21 VHT Vanguard Health Care ETF Vanguard 0.03% $7.3M — 2026-09-30
22 IJS iShares S&P Small-Cap 600 Value ETF iShares (BlackRock) 0.08% $6.1M $7.6B 2026-10-20
23 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.16% $4.9M $3.1B 2026-10-20
24 FNDA Schwab Fundamental U.S. Small Company ETF Nport 0.05% $4.7M — 2026-05-31
25 SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF SPDR (State Street) 0.08% $3.9M $4.7B 2026-10-20
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.92
TTM Revenue
$830.44M
TTM Net Income
$-109.89M
TTM Op. Cash Flow
$19.91M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$219.06M$-58.37M$-1.01$-4.81M
Q1 '262026-03-31$207.71M$-2.29M$-0.04$66.52M
Q4 '252025-12-31$211.57M$-4.11M$-0.07$19.86M
Q3 '252025-09-30$192.10M$-45.12M$-0.80$-61.66M
Q2 '252025-06-30$165.45M$22.50M$0.40$58.53M
Q1 '252025-03-31$149.82M$-11.83M$-0.21$30.60M
Q4 '242024-12-31$174.16M$15.33M$0.27$44.41M
Q3 '242024-09-30$175.69M$38.50M$0.69$53.52M
Q2 '242024-06-30$168.32M$19.92M$0.36$35.62M
Q1 '242024-03-31$143.64M$124.00K—$38.40M
Q4 '232023-12-31$164.31M$1.18M$0.02$43.65M
Q3 '232023-09-30$153.88M$-15.98M$-0.29$37.19M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-03
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.29
P/S
2.84
EV/EBITDA
76.28
EV/Sales
2.62
ROE
-10.7%
ROA
-7.7%
Div Yield
0.00%
FCF Yield
0.84%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.36B
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.99M
SI % of Float
8.98%
Days to Cover
7.38
Short Vol Ratio
73.9%
Free Float
55.54M
Float %
95.4%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-09-22